Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med.1999;340:115-126.
Toss H, Lindahl B, Siegbahn A, Wallentin L.for the FRISC study group. Prognostic influence of increased fibrinogen and C-reactive protein
levels in unstable coronary artery disease. Circulation.1997;96:4204-4210.
Berk BC, Weintraub WS, Alexander RW. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol.1990;65:168-172.
Biasucci LM, Vitelli A, Liuzzo G.
et al. Elevated levels of interleukin-6 in unstable angina. Circulation.1996;94:874-877.
Biasucci LM, Liuzzo G, Fantuzzi G.
et al. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first
2 days of hospitalization in unstable angina are associated with increased
risk of in-hospital coronary events. Circulation.1999;99:2079-2084.
Simon AD, Yazdani S, Wang W, Schwartz A, Rabbani LE. Circulating levels of IL-1 β, a prothrombotic cytokine, are elevated
in unstable angina vs stable angina. J Thromb Thrombolysis.2000;9:217-222.
Verheggen PW, de Maat MP, Cats VM.
et al. Inflammatory status as a main determinant of outcome in patients with
unstable angina, independent of coagulation activation and endothelial cell
function. Eur Heart J.1999;20:567-574.
Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L.for the FRISC study group. Markers of myocardial damage and inflammation in relation to long-term
mortality in unstable coronary artery disease. N Engl J Med.2000;343:1139-1147.
Mendall MA, Strachan DP, Butland BK.
et al. C-reactive protein: relation to total mortality, cardiovascular mortality
and cardiovascular risk factors in men. Eur Heart J.2000;21:1584-1590.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently
healthy men. N Engl J Med.1997;336:973-979. [published correction in N Engl
J Med. 1997;337:356].
Koenig W, Sund M, Frohlich M.
et al. C-Reactive protein, a sensitive marker of inflammation, predicts future
risk of coronary heart disease in initially healthy middle-aged men: results
from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease)
Augsburg Cohort Study, 1984 to 1992. Circulation.1999;99:237-242.
Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction
of cardiovascular disease in women. N Engl J Med.2000;342:836-843.
Harris TB, Ferrucci L, Tracy RP.
et al. Associations of elevated interleukin-6 and C-reactive protein levels
with mortality in the elderly. Am J Med.1999;106:506-512.
Barton BE. The biological effects of interleukin 6. Med Res Rev.1996;16:87-109.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial
infarction among apparently healthy men. Circulation.2000;101:1767-1772.
FRISC II Investigators. Long-term low-molecular-mass heparin in unstable coronary-artery disease:
FRISC II prospective randomised multicentre study. Lancet.1999;354:701-707. [published correction appears in Lancet. 1999;354:1478].
FRISC II investigators. Invasive compared with noninvasive treatment in unstable coronary-artery
disease: FRISC II prospective randomised multicentre study. Lancet.1999;354:708-715.
Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E.for the FRISC II Investigators. Outcome at 1 year after an invasive compared with a non-invasive strategy
in unstable coronary-artery disease. Lancet.2000;356:9-16.
Schieffer B, Schieffer E, Hilfiker-Kleiner D.
et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic
plaques: potential implications for inflammation and plaque instability. Circulation.2000;101:1372-1378.
Rader DJ. Inflammatory markers of coronary risk. N Engl J Med.2000;343:1179-1182.
Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular
ejection fraction: a report from the Studies of Left Ventricular Dysfunction
(SOLVD). J Am Coll Cardiol.1996;27:1201-1206.
Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. β-Adrenergic blockade in developing heart failure: effects on
myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation.2000;101:2103-2109. [published correction appears in Circulation. 2000;102:141].
Woods A, Brull DJ, Humphries SE, Montgomery HE. Genetics of inflammation and risk of coronary artery disease: the central
role of interleukin-6. Eur Heart J.2000;21:1574-1583.
Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6
the link? Atherosclerosis.2000;148:209-214.